Literature DB >> 19223799

Barriers to effective pain management in sickle cell disease.

Kerri Wright1, Omolola Adeosum.   

Abstract

Sickle cell disease (SCD) is a long-term condition that would benefit from a long-term conditions approach to its care and management. SCD is growing in prevalence, affecting 10,000-12,000 people in the UK, with SCD sufferers having an increased life expectancy from in the past. The most problematic aspect of managing SCD is management of the pain from vaso-occlusive crises. Vaso-occlusive pain is the most common reason for hospital admissions in people with SCD and accounts for large numbers of accident and emergency (A&E) attendances. A literature review was carried out to examine the management of vaso-occlusive pain in SCD. The review identified three main barriers to effective pain management in SCD: the manifestation of vaso-occlusive pain, the sociocultural factors affecting pain assessment, and the concerns regarding addiction and pseudo-addiction. Addressing these barriers will allow people with SCD to have their pain managed more effectively, improve their quality of life and potentially reduce A&E attendances and admissions to hospital.

Entities:  

Mesh:

Year:  2009        PMID: 19223799     DOI: 10.12968/bjon.2009.18.3.39043

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  18 in total

1.  A video-intervention to improve clinician attitudes toward patients with sickle cell disease: the results of a randomized experiment.

Authors:  Carlton Haywood; Sophie Lanzkron; Mark T Hughes; Rochelle Brown; Michele Massa; Neda Ratanawongsa; Mary Catherine Beach
Journal:  J Gen Intern Med       Date:  2010-12-23       Impact factor: 5.128

Review 2.  The management of sickle cell pain.

Authors:  Robert E Richard
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 3.  Improving Emergency Department-Based Care of Sickle Cell Pain.

Authors:  Jeffrey A Glassberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Perceived injustice predicts stress and pain in adults with sickle cell disease.

Authors:  Miriam O Ezenwa; Robert E Molokie; Diana J Wilkie; Marie L Suarez; Yingwei Yao
Journal:  Pain Manag Nurs       Date:  2014-10-31       Impact factor: 1.929

5.  Randomized clinical trial of computerized PAINRelieveIt® for patients with sickle cell disease: PAINReportIt® and PAINUCope®.

Authors:  Brenda W Dyal; Miriam O Ezenwa; Yingwei Yao; Robert E Molokie; Zaijie J Wang; Samir K Ballas; Marie L Suarez; Diana J Wilkie
Journal:  Patient Educ Couns       Date:  2019-08-17

6.  Differences in Sensory Pain, Expectation, and Satisfaction Reported by Outpatients with Cancer or Sickle Cell Disease.

Authors:  Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Yingwei Yao; Marie L Suarez; Brenda Dyal; Khulud Abudawood; Diana J Wilkie
Journal:  Pain Manag Nurs       Date:  2018-03-01       Impact factor: 1.929

7.  An unequal burden: poor patient-provider communication and sickle cell disease.

Authors:  Carlton Haywood; Shawn Bediako; Sophie Lanzkron; Marie Diener-West; John Strouse; Jennifer Haythornthwaite; Gladys Onojobi; Mary Catherine Beach
Journal:  Patient Educ Couns       Date:  2014-05-23

8.  Evaluation of a Sickle Cell Disease Educational Website for Emergency Providers.

Authors:  Mariam Kayle; Jill Brennan-Cook; Brigit M Carter; Anne L Derouin; Susan G Silva; Paula Tanabe
Journal:  Adv Emerg Nurs J       Date:  2016 Apr-Jun

9.  Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease.

Authors:  Carlton Haywood; Marie Diener-West; John Strouse; C Patrick Carroll; Shawn Bediako; Sophie Lanzkron; Jennifer Haythornthwaite; Gladys Onojobi; Mary Catherine Beach
Journal:  J Pain Symptom Manage       Date:  2014-04-15       Impact factor: 3.612

10.  Emergency provider analgesic practices and attitudes toward patients with sickle cell disease.

Authors:  Jeffrey A Glassberg; Paula Tanabe; Annie Chow; Katrina Harper; Carlton Haywood; Michael R DeBaun; Lynne D Richardson
Journal:  Ann Emerg Med       Date:  2013-04-03       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.